Corporate Research Group

Advanced Search

Home
Subscribe
 
Managed Healthcare
Market Report
HSA Market News
eHealth Insider
Research Reports
Conferences
Webinars
 
My Account
Contact Us
About Us
 




DIABETES: ASSESSING THE COMPETITIVE POTENTIAL OF EMERGING THERAPIES

Order Now!

CRG "Drugs in Pipeline" Series

Diabetes:
Assessing the Competitive Potential of Emerging Therapies


Executive Summary


Diabetes has been described as the epidemic of the 21st century, currently impacting the lives of more than 200 million people worldwide. Obesity, an important risk factor for diabetes, is growing at even a faster pace and likely to further increase the prevalence of diabetes.

The upshot is that payers already shelling out hundred of billions of dollars to treat diabetes will continue to embrace new therapies and treatments. And that spells opportunities for biotech and pharmaceutical investing in new solutions to these growing problems.

But which drugs in pipeline have the best prospects for success? And which pose the biggest competitive threat to existing—bestselling—diabetes drugs?

Diabetes: Assessing the Competitive Potential of Emerging Therapies is the latest installment in the CRG Drugs in Pipeline series. Written by leading pharmaceutical industry analysts Boas Gonen, M.D., a founder of BioPharma Guide and Ron Notvest, Ph.D., MBA, a founder of Evidec, this 200-page report provides has expert assessment of the prospect of diabetes drugs in the development.

New 100-Point Rating System


Many dozens of different drugs in development will be reviewed and rated on a scale of 1 to 100, using a newly developed proprietary algorithm which takes into account published information on product attributes, all of which are known to have an impact on the probability of success for a compound. The algorithm will include both qualitative and quantitative data, to address the following questions:

Preclinical data
    Is the preclinical model validated or known to be predictive?
    Is there in vivo data available?
    Is the pharmacological target relevant to the pathogenesis?
Clinical data
    Has proof-of-concept been demonstrated?
    Has the inherent safety been demonstrated?
Target validation
    Has the molecular target been validated?
    Has the safety been validated?
Regulatory Importance
    Is the compound known to be designated fast track?
    Is the compound receiving a priority review?
    Is there a highly significant medical need?
Likelihood of commercial success
    How differentiated is the product and will there be high demand?
Success of other compounds in the class
    Are there any approved products in this class?
    If so, are they differentiated?
Rating Drugs in Development and Assessing How the Competition Stacks Up


With the results of our proprietary 100-Point Rating System as a basis, this report will analyze all of the drugs in clinical development among both U.S. and international drug manufacturers, including Big Pharma, biotech, publicly traded companies, privately firms and start-ups. Our analysis will encompass treatments for Type II Diabetes, Type I Diabetes, Diabetic Complications and Obesity.
  • Type II Diabetes treatment to be rated will include…
      Insulins and analogues
      Injectable (Oral/Buccal, Inhaled, Other)
      GLP-1 and related compounds
      DPP-IV inhibitors
      PPAR activators
      Fructose 1.6 bipshosphatase inhibitors
      PTP-1B inhibitors
      11beta-HSD1
      Sodium-Glucose Reuptake Cotransporter-2 inhibitors
      AMP Kinase activators
      GK activators
      Others
      Natural products and diet supplements
  • Type I Diabetes treatment to be rated will include…
      Immune-modulators
      Stem Cells, Islet transplants
      Others
  • Obesity treatments to be rated will include…
      Centrally acting agents
      Peripherally acting agents
The State of the Art of Diabetes Development


The report will also provide an insightful overview of the strengths and weaknesses of existing treatments and players in the market for diabetes drugs, including…
  • Medical overview on diabetes and obesity: types, epidemiology, pathophysiology, manifestations, complications.
  • Current status of anti-diabetic therapy
      Available therapies
        Insulins
        Non-insulin injectables (e.g. Symlin, Byetta)
        Oral (e.g. Sulphonyl-ureas; Metformin; PPAR-ã agonists, CHO absorption inhibitors, Insulin stimulators, DPP IV inhibitors)
  • Current status of anti-obesity therapy
      Appetite suppressants
  • In depth analysis of recent setbacks in anti-diabetic/anti-obesity drugs
      Marketed:
        Troglitazone
        Avandia
      Pre-approval:
        Rimonabant
        Galvus
Profiles of Pharmaceutical, Biotech Firms in the Diabetes Space


The profiles will cover ~100 companies, including the following: Akesis, AmbRx, Arena, Bentley, Biodel, Biovitrum, Conjuchem, CytRx, Diamyd, Depomed, Diobex, Emisphere, Genaera, Generex, Incyte, Insulet, Isis, Kinemed, Lexicon, Merck, Metabolex, Metabasis, Microislet, Neurogen, Novartis, Novo-Nordisk, Nutrition 21, Opexa, Oramed, Orexigen, Phenomix, Protemix Transition, Vivus.

Who will benefit from reading this report?
  • Pharmaceutical companies: Executives, Scientists, Business development personnel
  • Managed care companies: senior executives, reimbursement managers
  • Investment companies: fund managers, VC partners
  • Individual biotech investors
  • Health care providers: General physicians, endocrinologists
About the Authors


Boas Gonen M.D.

Dr. Gonen has more than 25 years experience in academic medicine and the pharmaceutical industry. A board certified endocrinologist (sub-specialty in diabetes and lipid metabolism), Dr. Gonen has wide academic research experience and pharmaceutical drug development experience. Most recently (since 1999) Dr. Gonen was involved in pharmaceutical consulting in clinical and business development (as president of Pharmagon). He has reviewed and analyzed hundreds of compounds in development.

Ron Notvest Ph.D. MBA

Dr. Notvest has over 20 years of pharmaceutical industry experience discovering, developing and marketing pharmaceutical products. In 2002, Dr. Notvest founded Evidec to address the commercial needs of small to mid-sized biopharmaceutical companies by providing commercial assessments, marketing support and market planning services. He has conducted assessments in a broad range of therapeutic areas, and has developed proprietary models to quantify the commercial potential of drug development assets.

Table of Contents


Chapter 1: Executive Summary—The Diabetes Epidemic, Problems and Solutions
Chapter 2: The State of the Art in Diabetes Treatment—A Review of Current Drugs
Chapter 3: Rating Drugs in Development—A Proprietary 100-Point Algorithm
Chapter 4: Profiles of Pharmaceutical, Biotech Firms in the Diabetes Space


About Corporate Research Group


Corporate Research Group has been serving the healthcare marketplace for 164 years as the industry's leading source for breaking news, strategic intelligence, market research and custom consulting.

CRG products consist of print and electronic newsletters, e-mail updates, annual forecasts, webinars, and the unique Managed Care Access online information service. CRG’s various information products include the Managed Healthcare Market Report, HSA Market News, Outlook for Managed Care, and various print and electronic databases and special reports.

CRG is a division of World Health Holdings, organizer of the nationally acclaimed World Health Care Congress.


 $2,495.00 - Order by June 27, 2008 and save $500!


 $2,995.00 - Standard Price



Home | About Us | My Account | Subscribe | Contact Us
© 2008 Corporate Research Group, Inc. All rights reserved.
A Division of WRG Research, Inc.